UCLA researchers find way to help T cells fight melanoma longer
Boosting the p53 protein with an experimental drug may prevent immune cell exhaustion in laboratory experiments.

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that temporarily boosting a protein called p53 helped specially prepared immune cells stay stronger and kill more melanoma cells in laboratory experiments. The study, published in Frontiers in Immunology, focused on T cells, which are immune cells that help the body fight disease.
To address the problem of T cells becoming exhausted and losing their ability to attack, researchers treated human T cells with an experimental drug called navtemadlin. This drug temporarily increases the activity of p53, a protein known for helping to prevent cancer.
In the lab, the treated T cells showed fewer signs of exhaustion, had more energy, and developed characteristics that could help them last longer. When tested against melanoma cells, these cells were significantly more effective at killing the cancer cells than untreated T cells.
Kien Vuu, a Los Angeles-based physician and former UCLA assistant clinical professor, said the approach could offer a relatively simple way to strengthen existing treatments. Rather than adding another genetic modification, this approach adds a drug during the manufacturing step when a patient's T cells are being prepared in the lab.
The findings remain preliminary, as the experiments involved human cells in a dish rather than animals or people. Researchers will need to test the approach in animals and other types of cancer before moving into clinical trials.
Dosing will be critical because higher doses of the drug caused more T cells to die. The researchers found that lower doses produced the desired effects without substantially reducing the number of healthy cells.
Key facts
- UCLA researchers found that boosting p53 protein with navtemadlin helped T cells fight melanoma cancer cells longer in laboratory experiments.
- The experimental drug navtemadlin temporarily increases the activity of the p53 protein.
- Higher doses of the drug caused more T cells to die in laboratory tests.
Three perspectives
Neutral
The study involved human cells in a laboratory setting rather than testing on animals or people.
Positive
The treated T cells showed fewer signs of exhaustion and were significantly more effective at killing melanoma cells in the lab.
Negative
Higher doses of the drug caused more T cells to die, making precise dosing critical.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.